✅ Palantir Q3: power unlocked | Bullets #50
✅ Palantir Q3: power unlocked | Bullets #50
Palantir developments and the crowned “Tweet of the Week”
Editor: Emanuele Marabella
Hi, I’m Arny. Thank you for joining 3.181 investors who receive Palantir’s deepest research. Please hit the ❤️ button if you enjoy today’s article.
Bullets #50 live stream with Vince is Bullish. I highly encourage you to subscribe to him on X and YouTube!
Last week:
Palantir released its Q3 results, which showed Revenue above Guidance growing at +17% and a surprisingly high 29% EBIT Adjusted Margin. The stock reacted with a +20% pop. I discussed the key elements of the reports on Palantir Weekly, hosted by
.
I went even more in detail with
on his channel!HSBC upgrades Palantir to BUY with a $21 price target (from $16) appreciating the business acceleration.
Bank of America Analyst Mariana Perez raised her target price to $21 (from $18). Last year I shared why I believed Bank of America’s team was the one that best understood Palantir:
Palantir stock benefitted from a series of rating upgrades also from other analysts, apart from Tyler Radke, Citi, who reiterated his $10 target. To summarise:
Wolfe Research: $11 target from $8;
DA Davidson: $18 target from $15;
Goldman Sachs: $12 target from $11;
CFRA: $20 target from “Sell”.
RBC confirmed its $5 price target due to a “skinny beat and weak leading indicators.” It is preferable that I do not comment here.
Palantir’s Co-Founder
participated on Fox Business discussing AI and Israel:
“One of my proudest moments is when Isreal started working with Palantir” - Joe Lonsdale, Palantir Co-Founder and 8VC Managing Partner
Palantir’s Head of Commercial, Ted Mabrey, showed confidence in the $10bn Revenue path:
“The path to $10bn looks much less daunting than the path to $1bn did.” - Ted Mabrey, Palantir’s Head of Commercial
Palantir uploaded a video on how it is helping Cleveland Clinic unlock value:
“By connecting these two pieces of information (patient flow & staffing), we have managed to reduce time spent calculating bed capacity by 75%”. - Amy Teleron, MD at Cleveland Clinic
The NHS deal award has been delayed again, to mid-November. A true, never-ending saga!
☕️ Would you like to discuss Palantir and other companies with me and other investors passionate about spotting market asymmetries?
Join the Arny Investment Club!
With the cost of a cappuccino, you could support my research for you 😊
Tweet of the week
The community honors Bank of America’s Analyst Mariana:
Yours,
Arny
You can also reach me at:
Twitter X: @arny_trezzi
YouTube: arny_trezzi
Private Discord: arnytrezzi
Disclaimer: The views and opinions expressed above are current as of the date of this document and are subject to change without notice. Materials referenced above will be provided for educational purposes only. None of the above will include investment advice, a recommendation or an offer to sell, or a solicitation of an offer to buy, any securities or investment products.
thank you, great coverage ... epic tweet of the week hehe. cheers!